BridgeBio Pharma, Inc. (BBIO)

NASDAQ: BBIO · IEX Real-Time Price · USD
9.24
+0.16 (1.76%)
At close: Jun 24, 2022 4:00 PM
9.20
-0.04 (-0.43%)
After-hours: Jun 24, 2022 7:56 PM EDT

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 20212020201920182017
Revenue
69.728.2540.5600
Revenue Growth (YoY)
745.14%-79.66%---
Cost of Revenue
3.1102.500
Gross Profit
66.68.2538.0600
Selling, General & Admin
192.21145.6894.3543.5913.3
Research & Development
451.02337.05209.95140.0730.56
Operating Expenses
643.23482.73304.3183.6643.86
Operating Income
-576.63-474.48-266.24-183.66-43.86
Interest Expense / Income
46.7836.668.772.550.01
Other Expense / Income
-60.87-62.41-14.42-55.46-13.31
Pretax Income
-562.54-448.72-260.59-130.75-30.57
Net Income
-562.54-448.72-260.59-130.75-30.57
Net Income Common
-562.54-448.72-260.59-130.75-30.57
Shares Outstanding (Basic)
1441181056231
Shares Outstanding (Diluted)
1441181056231
Shares Change
22.34%12.27%70.15%101.86%-
EPS (Basic)
-3.90-3.80-2.48-2.12-1.00
EPS (Diluted)
-3.90-3.80-2.48-2.12-1.00
Free Cash Flow Per Share
-3.54-3.45-2.44-2.25-1.34
Gross Margin
95.53%100.00%93.84%--
Operating Margin
-827.12%-5751.99%-656.41%--
Profit Margin
-806.90%-5439.74%-642.47%--
Free Cash Flow Margin
-733.23%-4936.74%-631.72%--
EBITDA
-504.31-407.53-250.96-128.2-30.55
EBITDA Margin
-723.37%-4940.30%-618.75%--
Depreciation & Amortization
11.454.540.8600
EBIT
-515.76-412.07-251.82-128.2-30.55
EBIT Margin
-739.80%-4995.38%-620.86%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).